Compare Abeona Therapeutics Inc (ABEO) vs Adobe Systems Inc (ADBE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Adobe Systems Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Adobe Systems Inc trades at $220.61 (market cap $88.06B). The key difference: Adobe Systems Inc is far larger — about 235.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | ADBE | |
|---|---|---|
Market Cap | $373.32M | $88.06B |
Sector | Health | Technology |
52-Week High | $7.23 | $382.24 |
52-Week Low | $4.17 | $193.41 |
Enterprise Value | $228.22M | $89.50B |
Volume | — | 5,187,646 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Adobe (ADBE) trades at $220.35, up 1.05% with a bullish technical signal. The company reported strong Q1 2026 earnings of $5.96 EPS, beating estimates, and maintains robust profitability with 89.4% gross margins. Revenue growth accelerated to $23.77B in 2025, while valuation ratios remain attractive with P/E at 12.67. Recent institutional buying activity contrasts with some analyst concerns about AI competition.
Adobe presents a compelling investment case with strong fundamentals and growth trajectory, though AI disruption risks and recent stock volatility warrant caution. The consensus price target of $246.75 suggests 12% upside potential, supported by consistent earnings beats and expanding cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →
